• June 22, 2021

    Emalex Biosciences Announces Completion of Patient Enrollment in Phase 2b Clinical Trial Evaluating Ecopipam (EBS-101) for Pediatric Patients with Tourette Syndrome

    Paragon Biosciences’ Portfolio Company Focuses on Areas with [...]

  • June 3, 2021

    Sai Chavala, M.D., Receives ARVO Foundation Ludwig Von Sallmann Clinician-Scientist Award

    Dr. Chavala is co-founder of CiRC Biosciences with [...]

  • March 23, 2021

    Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials

    Funding led by Paragon Biosciences, joined by Fidelity [...]

  • March 10, 2021

    CiRC Biosciences Announces Orphan Drug Designation for Treatment of Retinitis Pigmentosa (RP)

    Cell Therapy Platform Seeks to Restore Vision for [...]

  • February 23, 2021

    Paragon Biosciences Appoints Jordan Dubow as Chief Medical Officer

    Chicago, February 23, 2021—With continued growth [...]

  • February 2, 2021

    Paragon Biosciences Launches CiRC Biosciences to Expand Cell and Gene Therapy Platform

    Its vision restoration technology featured in Nature and [...]

  • December 15, 2020

    First Patient Dosed in Emalex Biosciences Phase 2 Clinical Trial for Stuttering

    Chicago – December 15, 2020 – Emalex Biosciences, [...]

  • September 9, 2020

    Jon DeVries Named Qlarity Imaging Chief Executive Officer

    Chicago, September 9, 2020 – Life science innovator [...]